Letter to stakeholders

Dear Readers,

We are pleased to present the **third Sustainability Report** of the Petrone Group, prepared on a voluntary basis and covering the year **2024**.

This document narrates our journey, one that unites strategic vision, economic growth and a strong sense of responsibility towards communities and local areas.

In an international environment of geopolitical instability and economic uncertainty, our Group has maintained steady, broad-based growth, reinforcing our presence across each of the sectors in which we operate: from pharmaceutical distribution to pharmaceutical logistics, and from manufacturing to the health sector, paid parking and construction.

In 2024, we made decisive investments in broadening our range of services, advancing our **international expansion** efforts and maximising **organisational synergies**. These choices have not only strengthened our financial results, but have also created new opportunities to embed sustainability across every area of our business.

This is reflected in the expansion of our reporting boundary to include all the Group companies, including the international companies, and our adoption of the new European standards (CSRD and ESRS), which now enable us to provide a more comprehensive and transparent view of our organisation.

We have strengthened our sustainability governance by establishing the **Sustainability Committee** and appointing ESG representatives within the main Group companies and functions. This has resulted in a system that is increasingly robust, far-reaching and integrated throughout our decision-making processes.

On the cultural front, we launched the **"Values in Action"** initiative, which engaged us deeply in defining the core values that guide our actions. Among these, Sustainability has become central, reflecting its active and cross-cutting presence in our vision for the future. We have also made significant headway in environmental terms. For the first time in 2024, we calculated the Group's **Carbon Footprint**, including indirect emissions (Scope 3), laying the groundwork for a decarbonisation plan aligned with the European targets. To this end, Euromed Pharma Services joined the **Science Based Targets** (SBTi) initiative, formally pledging to reduce emissions in line with scientific recommendations.

Within ESG, Euromed Pharma and Euromed Pharma Services were awarded the **EcoVadis bronze** medal, while a structured project as launched to assess the sustainability of the supply chain through the same platform. Building constructive relationships with our commercial partners therefore means transparency, traceability and ongoing improvement.

Regarding our people, we introduced our first **Diversity, Equity & Inclusion Policy** and launched ESG training, which is set to become a long-term resource for reinforcing awareness of these matters at every level of the Group.

We also promoted the active participation of employees in **social** and **local projects**, strengthening bonds with organisations and associations nationwide. For us, being an enterprise means generating and sharing value with the communities of which we are a part.

Our progress on sustainability goes hand in hand with our economic growth. The results achieved and the projects launched in 2024 confirm that development and responsibility not only coexist, but also strengthen one another. That is why we will continue to integrate ESG criteria ever more deeply across all business lines, ensuring that every corporate decision helps to shape a more inclusive and regenerative future.

We hope these pages have succeeded in authentically conveying the profound significance of the journey we are undertaking together, and we thank you for your attention and trust you show us as you accompany us into the future.

We hope you enjoy reading this report.

Chief Executive Officer